Company
Inhibrx, Inc. (0001739614)
Standardized SEC financial data for Inhibrx, Inc. — income statement, balance sheet, cash flow and 40+ ratios, as a clean JSON API. CIK 0001739614 · Biological Products, (No Diagnostic Substances).
Operating margin
-1000.0%
Net margin
-1000.0%
Revenue growth (YoY)
-17.9%
Return on equity
-554.8%
Free cash flow
-$197.9M
Debt / equity
0.00×
Current ratio
5.25×
EPS (diluted)
$-5.12
Ratios for fiscal year 2023, standardized from SEC filings.
Income statement
| USD | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
| Revenue | $13.2M | $12.9M | $7.2M | $2.2M | $1.8M |
| R&D expense | $47.9M | $73.5M |
Balance sheet
| USD | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $2.1M | $11.5M | $128.7M | $131.3M | $273.9M | $277.9M |
| Total current assets |
Cash flow
| USD | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
| Operating cash flow | -$32.1M | -$48.0M | -$80.3M | -$115.3M | -$193.3M |
| Capital expenditures | $1.8M | $1.4M |
Get 0001739614 data via API
# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/0001739614/financials \
-H "X-API-Key: YOUR_KEY"
# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/0001739614/income-statement?format=csv" \
-H "X-API-Key: YOUR_KEY"